Cancer-associated Gene Mutations in CML Treatment With TKIs by NGS

Inclusion Criteria: 1. Chronic myeloid leukemia-Chronic phase(CML-CP) patients treated with receiveTyrosine kinase inhibitor -TKI(including imatinib, dasatinib and nilotinib) for more than 1 years 2. best effect to TKIs ,or intolerance to TKIs,or resistance to TKIs according to Q-pcr detected BCR/ABL(IS) in peripheral blood and hematologic response and cytogenetic response 3. Informed consent of the patient or his legal representative Exclusion Criteria: 1. Patients had history of CML-AP or CML-BC 2. CML Patients who have received allogeneic hematopoietic stem cell transplantation 3. CML Patients who have received immunotherapy (except interferon, including car-t and other cellular immunotherapy) 4. Woman who is pregnant or nursing